Mounjaro (Tirzepatide)
Solution for Injection in Pre-Filled KwikPen
$140.00$130.00
An MHRA-approved prescription treatment containing tirzepatide, a dual GIP and GLP-1 receptor agonist. Delivered via a multi-dose pre-filled KwikPen device for once-weekly subcutaneous administration, indicated for chronic weight management and type 2 diabetes regulation.
Mounjaro (tirzepatide) is a first-in-class dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly, Mounjaro activates both endogenous incretin pathways to enhance glycemic control, regulate appetite, slow gastric emptying, and promote sustained weight loss.
In the UK, Mounjaro is supplied as a 4-dose pre-filled multi-dose pen (KwikPen) intended for once-weekly subcutaneous injection. Treatment follows a mandatory dose-escalation schedule to optimize therapeutic efficacy while minimizing gastrointestinal side effects.
Key Clinical Indications
Weight Management: Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) in the presence of weight-related comorbidities.
Type 2 Diabetes Mellitus: Indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, either as monotherapy or alongside other glucose-lowering medicinal products.
Dosing & Escalation Schedule
Mounjaro is administered once weekly, on the same day each week, subcutaneously into the abdomen, thigh, or upper arm. The dosage must be titrated progressively:
Maintenance Stage | Weekly Dose | Duration | Purpose |
Initiation | 2.5 mg | Weeks 1–4 | Treatment initiation (non-therapeutic starting dose) |
Step 1 | 5.0 mg | Weeks 5–8 | Initial therapeutic dose |
Step 2 | 7.5 mg | Weeks 9–12 | Escalation step |
Step 3 | 10.0 mg | Weeks 13–16 | Escalation / maintenance dose |
Step 4 | 12.5 mg | Weeks 17–20 | Escalation step |
Maximum | 15.0 mg | Week 21+ | Maximum maintenance dose |
Product Specifications
Active Ingredient: Tirzepatide
Drug Class: Dual GIP/GLP-1 Receptor Agonist
Available Pen Strengths: 2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg, 12.5 mg, 15.0 mg (per dose)
Delivery Format: Pre-filled multi-dose KwikPen (contains 4 fixed weekly doses per pen)
Route of Administration: Subcutaneous injection
Prescription Status: POM (Prescription Only Medicine) / Requires Clinical Consultation
Storage & Handling Conditions
Unopened Pens: Store in a refrigerator between $2^\circ\text{C}$ and $8^\circ\text{C}$. Do not freeze. Protect from direct light.
In-Use Pens: Once first used, the pen can be stored below $30^\circ\text{C}$ or refrigerated ($2^\circ\text{C} - 8^\circ\text{C}$) for up to 30 days. Discard the pen 30 days after first use even if solution remains.
Prescription Disclaimer: Mounjaro is a Prescription Only Medicine (POM). Full medical assessment and prescription approval by a qualified healthcare professional are mandatory prior to dispensing.